Previously, we reported that inhibition of Cat D sensitized cancer cells to anticancer drugs through RNF183-mediated Bcl-xL degradation [16], and activation of NF-κB signaling is important for the induction of RNF183 expression. Here, BCL2L1 is linked to cancer.